Neuland Laboratories Limited — Q1FY27 earnings call summary

Filed 10 August 2026 · Official transcript

Working capital days improved to 84 from 137 in FY26; capex INR121.6 Cr for R&D and peptide facilities
FY27 growth expected around 20%, with no destocking risk in near term
EBITDA margin guidance around 25% long term; current quarter margin partly due to favorable conditions
Peptide plant commissioning next month; multiple projects lined up with commercial potential
Commercial CMS growth driven by handful of molecules; 1-2 new commercializations expected next year
Development pipeline improving; new molecules expected to replenish commercial base in 3-5 years
Land acquisition ongoing for short-term expansion; long-term plans include new manufacturing sites
Future capex to be larger and qualitatively different, focusing on complex modalities and possible geographic diversification